Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.59 |
| ▸ | CCND1 | P24385 | 1/20 | 0.59 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.50 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411835 | 0.91 | HTR1A (0.56) | CCNB2CDK1CDK4CCNB1CCND1 | |
| Perchlorate SCHEMBL10994108 | 0.90 | CCNB2 (0.50) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL28877513 | 0.90 | CCNB2 (0.53) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL28788684 | 0.90 | CCNB2 (0.52) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL4294807 | 0.89 | CCNB2 (0.55) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL1125006 | 0.89 | KDM4E (0.60) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL28129638 | 0.89 | KDM4E (0.60) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL16632680 | 0.88 | KMT2A (0.54) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL5839420 | 0.87 | CCNB2 (0.51) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL433401 | 0.86 | CCNB2 (0.72) | CCNB2CDK1CDK4CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-3274322-B1 | STABLE COMPOSITIONS FOR PREVENTION / PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS | THE UNIV OF MISSISSIPPI (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| EP-0228625-B1 | PEPTIDE DERIVATIVES INHIBITORS OF HYDROXYLING ENZYMES, THEIR PROCESS OF PREPARATION, THE AGENTS THEREOF AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-02 | — | — | EP | disclosed |
| EP-0401517-A1 | Substituted 2-alkynylphenols with anti-inflammatory action, a process for their preparation and pharmaceutical compositions thereof | CAMILLO CORVI S.p.A. (IT) | 1990-12-12 | — | — | EP | disclosed |
| EP-0339927-A2 | Amide compounds their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4797471-A | INHIBITING COLAGEN SYNTHESIS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-10 | — | — | US | disclosed |
| EP-0228625-A2 | Peptide derivatives inhibitors of hydroxyling enzymes, their process of preparation, the agents thereof and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-15 | — | — | EP | disclosed |
| EP-0189142-A2 | Arylalkoxyphenyl-allylic alcohols as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1986-07-30 | — | — | EP | disclosed |
| US-4529811-A | Process for isolating organic compounds and lithium salt complexes useful in said process | G. D. SEARLE & CO. (US) | 1985-07-16 | — | — | US | disclosed |
| US-4054617-A | LEATHER PROCESSING | DIAMOND SHAMROCK CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-3934975-A | Leather treating process | DIAMOND SHAMROCK CORPORATION (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | CCNB2 3540/4885CDK1 1651/4885CDK4 4605/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CCNB2 3540/4885CDK1 1651/4885CDK4 4605/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CCNB2 3540/4885CDK1 1651/4885CDK4 4605/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CCNB2 3540/4885CDK1 1651/4885CDK4 4605/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CCNB2 3540/4885CDK1 1651/4885CDK4 4605/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | CCNB2 3540/4885CDK1 1651/4885CDK4 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.